Apaluside contains Apalutamide, an oral anti-androgen medication used primarily in the treatment of prostate cancer. It works by blocking androgen receptors, preventing testosterone and other androgens from stimulating the growth of prostate cancer cells. Apaluside is usually prescribed for non-metastatic castration-resistant prostate cancer (nmCRPC) or in combination with other therapies in advanced stages.

Mechanism of Action

• Apalutamide binds to androgen receptors on prostate cancer cells, inhibiting androgen-driven gene expression.

• By blocking the effect of testosterone, it reduces cancer cell proliferation and slows tumor progression.

• Unlike traditional androgen deprivation therapy, Apalutamide directly targets the receptor rather than reducing testosterone production.

  Uses

  • Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

  • Can be used in combination with androgen deprivation therapy (ADT) in advanced prostate cancer.

  • Helps delay metastasis and prolong survival in patients with high-risk prostate cancer.

    Adverse Effects

    • Fatigue, weakness

    • Rash or skin reactions

    • Nausea, diarrhea

    • Hot flashes